Jennifer Fox
Equibles does not estimate personal net worth.
Get an email with a short summary when Myriad Genetics Inc publishes a filing, an earnings call transcript or a press release.
Get MYGN alertsAbout Jennifer Fox
Jennifer Fox is recorded as Board Member at Prokidney Corp. (PROK) and CFO at Zenas BioPharma, Inc. (ZBIO). The newest filing on record that lists Jennifer Fox as Board Member at Prokidney Corp. (PROK) is dated April 17, 2026. The newest filing on record that lists Jennifer Fox as CFO at Zenas BioPharma, Inc. (ZBIO) is dated March 16, 2026. Earlier roles on record: Board Member at Apogee Therapeutics, Inc. until August 11, 2026, General Counsel at Emergent BioSolutions Inc. (EBS) until August 16, 2024 and CFO at Nuvation Bio Inc. (NUVB) until November 27, 2023. Apogee Therapeutics, Inc. reported in an 8-K filed September 3, 2026 that Jennifer Fox resigned as director, effective September 3, 2026. Zenas BioPharma, Inc. reported in an 8-K filed August 13, 2026 that Jennifer Fox was appointed Strategic Advisor to the Board Chair, effective September 30, 2026. Apogee Therapeutics, Inc. reported in an 8-K filed August 11, 2026 that Jennifer Fox resigned as director. Equibles holds 5 filed executive changes naming Jennifer Fox; each is listed under recent activity with its source filing. The proxy statement of Emergent BioSolutions Inc. reports total compensation of $1,189,933 for Jennifer Fox in fiscal 2024, including a base salary of $472,658. Disclosed compensation is on record for 3 fiscal years. Myriad Genetics Inc is classified in the Diagnostics & Research industry within the Healthcare sector. Prokidney Corp. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Myriad Genetics Inc includes R. Bryan Riggsbee (CEO), R. Bryan Riggsbee Chief (CEO), Sam Raha (CEO and Board Member) and 7 others.
“In connection with the Merger and effective as of, and contingent upon, the Effective Time, all of the Company's directors (Michael Henderson, M.D., Mark C. McKenna, Lisa Bollinger, M.D., Jennifer Fox, William (BJ) Jones, Jr., Tomas Kiselak and Nimish Shah) voluntarily resigned from the Company's board of directors and the directors of Merger Sub immediately prior to the Effective Time became the directors of the Company.”
“The Company announced that Jennifer Fox will transition from her current role as Chief Financial Officer and Chief Business Officer to serve in a new role as Strategic Advisor to the Board Chair effective September 30th.”
Affiliation history
-
Zenas BioPharma, Inc. (ZBIO)
SEC 8-K
Current2026-09-30–present
-
Myriad Genetics Inc (MYGN)
Proxy statement
CurrentStart not stated–present
Last confirmed April 14, 2026
-
Current
Start not stated–present
Last confirmed April 17, 2026
-
Current
Start not stated–present
Last confirmed March 16, 2026
-
Apogee Therapeutics, Inc.
Board Member
Proxy statement
Start not stated–2026-08-11
-
Start not stated–2024-08-16
-
Start not stated–2023-11-27
Company network
Apogee Therapeutics, Inc.
Biotechnology · Healthcare
Board Member
Drug Manufacturers - Specialty & Generic · Healthcare
General Counsel
Leadership on record at Myriad Genetics Inc
- R. Bryan Riggsbee CEO
- R. Bryan Riggsbee Chief CEO
- Sam Raha CEO, Board Member
- Samraat Raha CEO, COO, Board Member
- Samraat S. Raha CEO, Board Member
- Ben R. Wheeler CFO
- Benjamin R. Wheeler CFO
- Bryan Riggsbee CFO
- Scott Leffler CFO
- Mark S. Verratti COO
Leadership on record at Prokidney Corp.
- Bruce Culleton CEO, Board Member
- Bruce Culleton, MD CEO, Board Member
- Pablo Legorreta Chairman, Board Member
- James Coulston CFO
- Alan M. Lotvin Board Member
- Brian J.G. Pereira Board Member
- José Ignacio Jiménez Santos Board Member
- Marc Semigran Board Member
- Tim Bertram Board Member
- Uma Sinha Board Member
Leadership on record at Zenas BioPharma, Inc.
- Leon O. Moulder CEO
- Joseph L. Farmer COO
- Christy J. Oliger Board Member
- Hongbo Lu Board Member
- Hongbo Lu, Ph.D. Board Member
- Jake Nunn Board Member
- James Boylan Board Member
- John Orloff Board Member
- Leon O. Moulder, Jr. Board Member
- Patricia Allen Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Emergent BioSolutions Inc. (EBS) | Former Executive Vice President, External Affairs, General Counsel and Corporate Secretary | $472,658 | $1,189,933 |
| 2024 | Zenas BioPharma, Inc. (ZBIO) | Chief Business Officer and Chief Financial Officer | $500,000 | $4,835,306 |
| 2023 | Emergent BioSolutions Inc. (EBS) | Former Executive Vice President, External Affairs, General Counsel and Corporate Secretary | $585,692 | $2,131,320 |
| 2023 | Zenas BioPharma, Inc. (ZBIO) | Chief Business Officer and Chief Financial Officer | $40,064 | $2,566,608 |
| 2022 | Emergent BioSolutions Inc. (EBS) | Former Executive Vice President, External Affairs, General Counsel and Corporate Secretary | $473,544 | $2,923,207 |
| 2022 | Nuvation Bio Inc. (NUVB) | Chief Financial Officer | $546,000 | $3,974,694 |